Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
16.27
-0.35 (-2.11%)
At close: Feb 21, 2025, 4:00 PM
16.50
+0.23 (1.41%)
After-hours: Feb 21, 2025, 7:01 PM EST
Viridian Therapeutics Employees
Viridian Therapeutics had 94 employees as of December 31, 2023. The number of employees increased by 8 or 9.30% compared to the previous year.
Employees
94
Change (1Y)
8
Growth (1Y)
9.30%
Revenue / Employee
$3,213
Profits / Employee
-$2,734,936
Market Cap
1.29B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
VRDN News
- 16 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire
- 2 months ago - Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
- 2 months ago - Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
- 2 months ago - Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) - Seeking Alpha
- 2 months ago - Viridian Therapeutics' eye disorder drug meets late-stage study goal - Reuters
- 2 months ago - Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire
- 2 months ago - Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire